All News

20 April 2009

AACR 100th Annual Meeting Highlights Superior Ability of InNexus’ DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical StudiesAntibodies

20 April 2009

Immunomedics Expands Product Pipeline for Potential Therapy of Cancer and Inflammatory DiseasesAntibodies

20 April 2009

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer TrialAntibodies

20 April 2009

Medarex Announces Clinical Data for MDX-1401 in Hodgkin’s Lymphoma at Annual Meeting of the American Association for Cancer ResearchAntibodies

20 April 2009

AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299)Antibodies

10 April 2009

ArmaGen plans First in Human clinical trialAntibodies

8 April 2009

Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. MarketAntibodies

8 April 2009

BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventisAntibodies

8 April 2009

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor GrowthAntibodies

6 April 2009

Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7Antibodies

6 April 2009

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With MillenniumAntibodies

3 April 2009

Arzerra (TM) (ofatumumab) granted priority review by FDAAntibodies

1 April 2009

GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, USAntibodies

25 March 2009

Alnara Pharmaceuticals Licenses Worldwide Rights to Liprotamase from Cystic Fibrosis FoundationAntibodies

25 March 2009

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and ImmunologyAntibodies

25 March 2009

Regeneron Announces Initiation of Phase 3 Gout Program with ARCALYST(R) (rilonacept)Antibodies

24 March 2009

Biovitrum gets access to Affibody® TechnologyAntibodies

24 March 2009

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted AntibodiesAntibodies

24 March 2009

Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit NeovascularizationAntibodies

23 March 2009

Xencor Licenses Xtend Antibody Half-Life Prolongation Platform to Merck & Co., Inc.Antibodies

23 March 2009

Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian CancerAntibodies

23 March 2009

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer PatientsAntibodies

19 March 2009

Neoprobe’s Phase 3 Lymphoseek Study Achieves Positive ResultsAntibodies

18 March 2009

Provenance Biopharmaceuticals Corp. Announces License Agreement with Merck Serono for the Development and Commercialization of Novel Immunocytokine for the Treatment of CancerAntibodies

18 March 2009

Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancerAntibodies

18 March 2009

InflaRx Closes Funding to Move Its Complement Antibody Program into Clinical Trials for Sepsis TreatmentAntibodies

17 March 2009

Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax DiseaseAntibodies

16 March 2009

YM BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND TRIAL OF NIMOTUZUMAB IN NON-SMALL-CELL LUNG CANCERAntibodies

12 March 2009

Biothera Receives Approval to Launch Two Phase II Lung Cancer TrialsAntibodies

12 March 2009

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TSLP Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis